advertisement
Abstract #27488 Published in IGR 12-4
Tolerability and effectiveness of preservativefree dorzolamide-timolol (preservative-free COSOPT((registered trademark))) in patients with open-angle glaucoma or ocular hypertension
Hutnik C; Neima D; Ibrahim F; Scott R; Vaillancourt J; Haine D; Sampalis JS; Bastien N; Foucart SClinical Ophthalmology 2010; 4: 581-590
Purpose: To assess the effect of preservative-free dorzolamide-timolol on nonvisual symptoms and intraocular pressure (IOP) in newly diagnosed and untreated patients with open-angle glaucoma or ocular hypertension. Methods: This was a prospective, 8-week, open-label, Canadian multicenter study. All patients were treated with preservative-free dorzolamide-timolol formulation. The primary outcome was the change in the nonvisual symptom score of the Glaucoma Symptom Scale (GSS-SYMP-6) from baseline to 8 weeks. Secondary effectiveness outcome measures were absolute and percent changes in IOP from baseline to 4 and 8 weeks. Results: One hundred and seventy-eight patients were enrolled. Mean (SD) age was 65.6 (12.1) years and 90 (50.6%) were females. There were 92 patients diagnosed with open-angle glaucoma, 62 with ocular hypertension, and 23 with both diseases (diagnosis was missing for one patient). The mean (SD) GSS-SYMP-6 score increased from 73.6 (21.8) at baseline to 76.1 (20.7) at 8 weeks (P = 0.097). Mean (SD) IOP significantly decreased by 11.7 (5.1) mmHg at 4 weeks (P< 0.001) and by 11.5 (5.3) mmHg at 8 weeks (P< 0.001), representing reductions of-38.5% (P< 0.001) and-38.0% (P< 0.001), respectively. Conclusion: Preservative-free dorzolamide-timolol does not increase eye discomfort while significantly reducing IOP in patients with open-angle glaucoma or ocular-hypertension. (copyright) 2010 Hutnik et al.
C. Hutnik. Department of Ophthalmology and Pathology, Ivey Eye Institute, St Joseph Health Care London, 268 Grosvernor Street, London, ON, N6A 4V2, Canada. cindy.hutnik@sjhc.london.on.ca
Classification:
11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (Part of: 11 Medical treatment)
